Sanofi US News

Nasal allergy sufferers now have the most effective player on their team to relieve even the toughest nasal allergy symptoms

New investigational PCSK9 inhibitor shown to significantly reduce LDL-C among Japanese patients

Approval reinforces the safety profile of Adacel as an active booster immunization for the prevention of tetanus, diphtheria, and pertussis

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT

Fewer Moms are Aware of Prescription Treatments for Head Lice Compared to OTC Yet Those Who Used an Rx Report Greater Satisfaction

First and only medicine in its class approved for over-the-counter use that provides 24 hour relief of the full range of nasal allergy symptoms including nasal congestion

Pathway to Stop Diabetes will provide funding for innovative diabetes researchers

- Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment -

Developing approaches for involving patients in drug development

- Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal -

- EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus® -

- Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints -

- Nasal Spray Treats Adults and Children with Seasonal and Year-Round Nasal Allergies -

Event Builds on Tradition of Corporate Citizenship and Community

New online resource provides customized tools, resources developed by leading Grandparent Expert to help grandparents learn more about highly contagious, often serious disease

- Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin -

Campaign harnesses positive peer influence and power of social media to help drive flu vaccination among #FLUgitives

-- Addition of Iconic Brand Bolsters U.S. Consumer Healthcare Business --

- Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy -

- Majority of Survey Respondents Reported They or Their Child Experienced a Severe Allergic Reaction While Traveling -